Glenmark Pharmaceuticals Ltd Share Price (GLENMARK)
as on
| Source : NSE
🔔 Earnings Alert
Glenmark Pharmaceuticals reports Q1 FY26 net profit fell 86% YoY to ₹46.97 crore due to litigation provisions.
Glenmark Pharmaceuticals Ltd Stock Performance
as on August 14, 2025 at 4:01 PM IST
Day's Low
Day's High
₹2,017₹2,052.8
1.35%
Downside
0.40%
Upside
52 Week's Low
52 Week's High
₹1,275.5₹2,284.837.62%
Downside
11.75%
Upside
| Market Stats | |
| Previous Close | ₹2,029.30 |
| Open | ₹2,039.30 |
| Volume | 9.86L |
| Upper Circuit | ₹2,232.20 |
| Lower Circuit | ₹1,826.40 |
| Day's Low | ₹2,017 |
| Day's High | ₹2,052.8 |
| 52 Week Low | ₹1,275.5 |
| 52 Week High | ₹2,284.8 |
| Returns % | |
| 1 Month Return | -7.27 % |
| 3 Month Return | + 41.14 % |
| 1 Year Return | + 30.58 % |
| 3 Year Return | + 425.27 % |
| 5 Year Return | + 325.38 % |
Glenmark Pharmaceuticals Ltd Stock Fundamentals & Key Indicators
Check Glenmark Pharmaceuticals Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹57,698.78 Cr
Return on Equity (ROE)
6.98
PE Ratio (TTM)
76.58
Return on capital employed (ROCE)
9.75
Industry PE ratio
43.28
Beta (LTM)
0.74
P/B Ratio
1.18
Dividend Yield
0.26
PEG Ratio
1.05
Quarterly Earnings Growth YOY
-86.2
EPS (TTM)
-50.8
Sector
Pharmaceuticals
Book Value
278.11
Technical Analysis
Neutral
View Technical Analysis
Glenmark Pharmaceuticals Ltd Stock's Interest Amongst Investors
Glenmark Pharmaceuticals Ltd Stock Valuation
Track how Glenmark Pharmaceuticals Ltd P/E has moved over time to understand its valuation trends.
Glenmark Pharmaceuticals Ltd in the last 5 years
Lowest (-275.05x)
December 28, 2023
Industry (43.28x)
August 14, 2025
Today (76.58x)
August 14, 2025
Highest (95.94x)
September 14, 2023
Today’s Price to Earnings Ratio: 76.58x
Glenmark Pharmaceuticals Ltd Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Glenmark Pharmaceuticals Ltd.
based on 11 analysts
81.82%
Buy
9.09%
Hold
9.09%
Sell
81.82% of analysts recommend a 'BUY' rating for Glenmark Pharmaceuticals Ltd. Average target price of ₹2124.18
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Share Price Target
Get share price movements and forecasts by analysts on Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd price forecast by 11 analysts
Upside of3.89%
High
₹2934
Target
₹2124.18
Low
₹1500
Glenmark Pharmaceuticals Ltd target price ₹2124.18, a slight upside of 3.89% compared to current price of ₹2044.6. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glenmark Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:41.82%
Forecast
Actual
Including amortisation and stock based compensations
Glenmark Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Financial Results
Get the annual and quarterly financial summary of Glenmark Pharmaceuticals Ltd, including revenue, profit, loss and more.
Glenmark Pharmaceuticals Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd Earnings Results
Glenmark Pharmaceuticals Ltd’s net profit fell -86.23% since last year same period to ₹46.87Cr in the Q1 2025-2026. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated 907.96% jump in its net profits since last 3-months.
Read More about Earnings ResultsGlenmark Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 per share on 24 May 2024 - translating a dividend yield of 0.12%.
Read More about Dividends
Indices Featuring Glenmark Pharmaceuticals Ltd Stock
Check stock indices that include Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Glenmark Pharmaceuticals Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.65% | 0.00 | |
| Foreign Institutions | 20.62% | ||
| Mutual Funds | 15.55% | 20.92 | |
| Retail Investors | 15.06% | ||
| Others | 2.12% | 19.47 |
Glenmark Pharmaceuticals Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Glenmark Pharmaceuticals Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 57,698.78 | 65.08% | 0.59 | -1,434 | 11,813 | |
| BUY | 34,960.90 | 32.7% | 0.52 | 300 | 1,051 | |
| BUY | 16,822.08 | 9.76% | 0.71 | 836 | 7,234 | |
| NA | 4,551.09 | -4.29% | 1.88 | -343 | 71 | |
| BUY | 15,765.90 | 48.97% | 0.67 | 244 | 1,515 |
Glenmark Pharmaceuticals Ltd News & Key Events
Latest news and events in one place to help you make informed investing decisions in Glenmark Pharmaceuticals Ltd.
Glenmark Q1 Profit Plummets Amid US Settlement - 14 Aug, 2025
Glenmark Pharmaceuticals reported an 86% decline in Q1 profit to ₹46.8 crore, impacted by a US settlement provision. Revenue remained stable, showing a slight increase.Glenmark Pharma Settles Antitrust Suit, Shares Rise - 07 Aug, 2025
Glenmark Pharmaceuticals' US arm has reached a $37.75 million settlement in an antitrust lawsuit, leading to a 1% increase in share price. The settlement addresses allegations of price fixing and market allocation in the generic medication sector.Glenmark Faces USFDA Warning Amid Positive Rating Outlook - 23 Jul, 2025
Glenmark Pharmaceuticals received a Positive outlook revision from India Ratings for its long-term bank facilities. However, the USFDA issued a warning letter citing significant CGMP violations at its Pithampur plant, highlighting serious manufacturing lapses.Glenmark Pharma Shows Bullish Momentum for Breakout - 21 Jul, 2025
Glenmark Pharma has formed a bullish pennant pattern, indicating a potential breakout towards ₹2,280. The hourly RSI at 59 suggests strengthening momentum, with a buy recommendation at ₹2,225.50. A drop below ₹2,194 would invalidate this bullish setup.
Insights on Glenmark Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 4.65 Cr → 46.87 Cr (in ₹), with an average increase of 90.1% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.86% to 15.55% in Jun 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 3 months, GLENMARK stock has moved up by 41.1%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 3.26K Cr → 3.29K Cr (in ₹), with an average increase of 0.7% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 46.65% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 32.3% return, outperforming this stock by 1.8%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 23.16% to 20.62% in Jun 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 15.56% to 15.06% in Jun 2025 quarter
About Glenmark Pharmaceuticals Ltd
Revenue: ₹3,059.33Cr as on June 2025 (Q1 FY26)
Net Profit: ₹46.97Cr as on June 2025 (Q1 FY26)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
| Organisation | Glenmark Pharmaceuticals Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| CEO | Glenn Saldanha |
| E-voting on shares | Click here to vote |
Mutual Funds that own Glenmark Pharmaceuticals Ltd Stock
Check out the Mutual Funds with significant holdings in Glenmark Pharmaceuticals Ltd.
FAQs
What is Glenmark Pharmaceuticals Ltd share price today?
Glenmark Pharmaceuticals Ltd share price today stands at ₹2044.6, Open: ₹2039.3, Previous Close: ₹2029.3, High: ₹2052.8, Low: ₹2017, 52 Week High: ₹2284.8, 52 Week Low: ₹1275.5 as on .
How to buy Glenmark Pharmaceuticals Ltd shares ?
To buy Glenmark Pharmaceuticals Ltd shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for GLENMARK or Glenmark Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Glenmark Pharmaceuticals Ltd shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Glenmark Pharmaceuticals Ltd?
Today's traded volume of Glenmark Pharmaceuticals Ltd is 9.86L. Which means that 9.86L shares of Glenmark Pharmaceuticals Ltd were bought and sold on the stock market during today's trading session.
What is Glenmark Pharmaceuticals Ltd's market cap today?
Today's market capitalisation of Glenmark Pharmaceuticals Ltd is ₹57,698.78 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd’s 52 week high is ₹2284.8 and 52 week low is ₹1275.5. The current share price of Glenmark Pharmaceuticals Ltd is ₹2044.6, which is -10.51% down from its 52 week high and 60.30% up from its 52 week low.